Technology
Duke-NUS marks 20 years with transformative S$30m in philanthropic gifts and pledges to boost next-gen medical breakthroughs
The legacy of Duke-NUS\' founding donor,the Estate of Khoo Teck Puat,continues with a transformative S$5.5 million gift towards research.
Future Minerals Forum to Announce Major Agreements Worth Billions
RIYADH,Saudi Arabia,Jan. 11,2025-- The highly anticipated fourth edition of the Future Minerals Forum,set to take place from January 14 to 16,2025,in Riyadh,is set to announce big agreements worth bi
Bananas hanging onto drones: See how the low-altitude economy matches with agriculture
BEIJING,Jan. 10,2025--A news report from China.org.cn on China\'s low-altitude economy:  
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform,similar to the preclinical stage KAT6 inhibitor (MEN2312) licen
Tuya Smart Showcases Popular AI Innovations at CES 2025, Defining a New Standard for Future Smart Living
LAS VEGAS,Jan. 10,2025-- Tuya Smart (NYSE: TUYA,HKEX: 2391),a global cloud platform service provider,presented its cutting-edge innovations at CES 2025,which not only showcased numerous cutting-edge t
Tuya Smart Hosts Successful 'Tuya Developer Day' During CES 2025, Leading Industry Change with Innovative AI Technology
LAS VEGAS,Jan. 10,2025-- Tuya Smart (NYSE: TUYA,HKEX: 2391),a global cloud platform service provider,successfully hosted its highly anticipated Tuya Developer Day event during CES 2025.
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
CAMBRIDGE,Mass.,ROTTERDAM,Netherlands and SHANGHAI,Jan. 10,2025--Harbour BioMed (HKEX: 02142,the "Company"),a global biopharmaceutical company committed to the discovery,development and com
DIOSynVax Announces a new Advisory Board as it drives the clinical development of its NextGen Influenza Vaccines including Bird-Flu
CAMBRIDGE,England and SAN DIEGO,Jan. 9,2025-- DIOSynVax,a clinical-stage biotechnology company at the forefront of developing innovative,broadly protective vaccines,built on the safety demonstrated by
OneTrust Expands International Footprint with New Singapore Office
OneTrust grows its presence in APAC to meet regional demand for solutions enabling responsible data and AI use
Invitation to media and analyst briefing for Ericsson Q4 2024 report
Report to be released at approximately 7:00 AM CET on January 24,2025 One live video webcast for analysts,investors,and journalists at 9:00 AM CET